Mediastinal mass as a rare manifestation of paragonimiasis in a pediatric patient: a case study and examination of diagnostic difficulties - Scorecard - MDSpire

Mediastinal mass as a rare manifestation of paragonimiasis in a pediatric patient: a case study and examination of diagnostic difficulties

  • By

  • Shuchun Yang

  • Li Song

  • Qingwei Guo

  • February 16, 2026

  • 0 min

Share

Clinical Scorecard: Mediastinal mass as a rare manifestation of paragonimiasis in a pediatric patient: a case study and examination of diagnostic difficulties

At a Glance

CategoryDetail
ConditionParagonimiasis
Key MechanismsZoonotic disease caused by food-borne trematodes of the genus Paragonimus, leading to respiratory and ectopic infections.
Target PopulationPediatric patients, particularly in endemic regions such as Asia.
Care SettingHospital setting with access to imaging and surgical intervention.

Key Highlights

  • Unusual presentation of paragonimiasis as a mediastinal mass in a pediatric patient.
  • Initial misdiagnosis of pneumonia complicated by mediastinitis.
  • Histopathological examination revealed multiple parasitic cysts.
  • Individualized treatment with praziquantel led to complete resolution of symptoms.
  • Challenges in diagnosis due to nonspecific symptoms and imaging findings.

Guideline-Based Recommendations

Diagnosis

  • Consider paragonimiasis in differential diagnosis for mediastinal masses, especially in endemic areas.
  • Utilize imaging studies such as CT for initial assessment.

Management

  • Administer praziquantel based on clinical and imaging findings.
  • Consider surgical intervention for definitive diagnosis and treatment.

Monitoring & Follow-up

  • Follow-up imaging may be advised to ensure resolution, although patient compliance may vary.

Risks

  • Potential for misdiagnosis due to overlapping symptoms with other conditions like lymphoma and tuberculosis.

Patient & Prescribing Data

Pediatric patients with suspected paragonimiasis.

Individualized dosing of praziquantel (25 mg/kg, twice daily for 15 days) based on clinical presentation.

Clinical Best Practices

  • Thorough history-taking to identify potential exposure to undercooked freshwater crustaceans.
  • Comprehensive imaging and laboratory tests to rule out other conditions.

Related Resources & Content

Original Source(s)

Related Content